Research Paper Volume 11, Issue 17 pp 7187—7196

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway

Figure 6. Proposed model. Pictures showing that AZ628 and BP-1-102 combination inhibits RAS-mutant lung cancer cells by markedly abrogating MEK/ERK signaling pathway activation.